Testosterone is associated with a greater risk for development and progression of metabolic syndrome, particularly in transmasculine individuals, according to a study published online July 2 in JAMA Network Open. Leila Hashemi, M.D., from the David Geffen School of Medicine in Los Angeles, and colleagues assessed whether gender-affirming hormone treatment (GAHT) by proxy steroid is associated with development and progression of metabolic syndrome. The analysis included 645 transgender participants and 645 matched cisgender participants. The researchers found that metabolic syndrome z-scores changed significantly over time and differed significantly across groups. Read More